New and Emerging Therapies for Retinal Disease: A Year in Review 

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.

Faculty

Carl D. Regillo, MD

Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania, United States

Disclosures

Carl D. Regillo, MD, has the following relevant financial relationships:
Consultant or advisor for: Adverum; Aldeyra; Allergan; Annexon; Apellis; Chengdu Kanghong; EyePoint; Genentech; Graybug; Iveric Bio; Kodiak; Lineage; Merck; NGM Bio; Notal; Novartis; Ocugen; REGENXBIO; Stealth; Takeda; Thea, Zeiss
Research funding from: Adverum; Allergan; Annexon; Apellis; Astellas; Chengdu Kanghong; EyePoint; Genentech; Graybug; Iveric Bio; Kodiak; Lineage; NGM Bio; Notal; Novartis; Opthea; Regeneron; REGENXBIO
Contracted researcher for: Adverum; Allergan; Annexon; Apellis; Astellas; Chengdu Kanghong; EyePoint; Genentech; Graybug; Iveric Bio; Kodiak; Lineage; NGM Bio; Notal; Novartis; Opthea; Regeneron; REGENXBIO
Stock options from: Iveric Bio
Owns stock (publicly traded) in: Ocugen

Adnan Tufail, MB, BS, MD, FRCOphth

Professor of Ophthalmology
Institute of Ophthalmology
University College London
Consultant Ophthalmologist
Moorfields Eye Hospital
London, United Kingdom

Disclosures

Adnan Tufail, MB, BS, MD, FRCOphth, has the following relevant financial relationships:
Consultant or advisor for: Allergan; Annexon; Apellis; Bayer; Genentech; Iveric Bio; Novartis; Oxurion; Roche; Thea
Speaker or member of speakers bureau for: Apellis; Thea
Research funding from: Bayer; Novartis
Ownership interest: Oculogics

Editor

Katherine Carpenter, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Katherine Carpenter, PhD, has the following relevant financial relationship:
Advisor or consultant for: Eisai (former), GW Pharmaceuticals (former)

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.